Huang Ding-Sen, Liu Ting-Ting, Lu Wei-Ting, Wang Chih-Chi, Lin Chih-Che, Yong Chee-Chen, Chen Kuang-Den, Liu Yueh-Wei, Kuo Yuan-Hung, Yen Yi-Hao, Hu Tsung-Hui, Tsai Ming-Chao
Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung, Taiwan.
Department of Pathology, Kaohsiung Chang, Gung Memorial Hospital, Chang Gung University College of Medicine Kaohsiung, Taiwan.
Am J Cancer Res. 2022 Jun 15;12(6):2659-2672. eCollection 2022.
Microscopic vascular invasion (MVI) is a strong risk factor associated with tumor recurrence and poor overall survival (OS) among hepatocellular carcinoma (HCC) patients after resection. Two types of MVI are identified: portal vein and capsular vein invasion. However, little is known about the impact of different types of MVI on HCC recurrence. The present study aimed to compare HCC recurrence and OS between the portal vein and capsule vein MVI. Patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A HCC who underwent primary resection between January 2001 and June 2016 were consecutively recruited. Factors that influenced OS and recurrence-free survival (RFS) were analyzed using Cox proportional hazards models. Of the 857 eligible patients, 327 (38.2%) had MVI, and 530 (61.8%) were without MVI. Of the 327 patients with MVI, 85 (26.0%) were with portal vein, 178 (54.4%) with capsular vein, and 64 (19.6%) with both-MVI type. Patients with both-MVI type suffered from a higher proportion of BCLC stage A ( < 0.001), capsular invasion ( = 0.002), and satellite nodules ( < 0.001). Both-MVI type is an independent risk factor for HCC recurrence (hazard ratio [HR]: 1.69; 95% CI, 1.22-2.36, = 0.002) and mortality (HR: 2.29; 95% CI, 1.59-3.29, < 0.001) compared with non-MVI. We further found that both-MVI type was significantly associated with a higher risk of extrahepatic recurrence (EHR) (HR: 8.74; 95% CI, 2.38-32.03, = 0.001). Among HCC patients after curative resection, concurrent portal and capsular MVI is a risk factor for HCC recurrence, especially for EHR, in comparison with non-MVI or only portal or capsular MVI alone.
微血管侵犯(MVI)是肝细胞癌(HCC)患者切除术后肿瘤复发和总体生存率(OS)较差的一个重要危险因素。已识别出两种类型的MVI:门静脉侵犯和包膜静脉侵犯。然而,对于不同类型的MVI对HCC复发的影响知之甚少。本研究旨在比较门静脉MVI和包膜静脉MVI患者的HCC复发情况及OS。连续纳入2001年1月至2016年6月期间接受初次切除的巴塞罗那临床肝癌(BCLC)0期或A期HCC患者。使用Cox比例风险模型分析影响OS和无复发生存期(RFS)的因素。在857例符合条件的患者中,327例(38.2%)有MVI,530例(61.8%)无MVI。在327例有MVI的患者中,85例(26.0%)为门静脉侵犯,178例(54.4%)为包膜静脉侵犯,64例(19.6%)为双发MVI类型。双发MVI类型患者中BCLC A期比例更高(<0.001)、包膜侵犯比例更高(=0.002)以及卫星结节比例更高(<0.001)。与无MVI相比,双发MVI类型是HCC复发(风险比[HR]:1.69;95%可信区间[CI],1.22 - 2.36,=0.002)和死亡(HR:2.29;95%CI,1.59 - 3.29,<0.001)的独立危险因素。我们进一步发现双发MVI类型与肝外复发(EHR)风险显著相关(HR:8.74;95%CI,2.38 - 32.03,=0.001)。在根治性切除术后的HCC患者中,与无MVI或仅门静脉或包膜静脉单一侵犯相比,门静脉和包膜静脉并发MVI是HCC复发的危险因素,尤其是EHR的危险因素。